Linked Life Data

19728025

Source:http://linkedlifedata.com/resource/pubmed/id/19728025

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
4
pubmed:dateCreated
2010-1-21
pubmed:abstractText
The initial treatment of multiple myeloma (MM) experienced a paradigm shift, in the past decade, with the introduction of novel agents such as thalidomide, lenalidomide and bortezomib, leading to improved outcomes. High dose therapy and autologous stem cell transplantation remain an important therapeutic option for patients with MM eligible for the procedure. However, most of these treatment regimens are too expensive for Chinese patients. Therefore, we investigated the effects of artesunate, which is commonly used in the treatment of severe malaria, on inhibition of proliferation and induction of apoptosis of a mouse myeloma cell line SP2/0. The growth inhibition of SP2/0 cell proliferation induced by artesunate (ART) treatment was measured using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method and the rate of apoptosis and cell cycle changes induced by ART were analyzed by flow cytometry. ART-induced morphology changes of apoptosis in SP2/0 cells, as observed by light and transmission electron microscopy. Additionally, DNA laddering, which is a hallmark of apoptosis, was observed by agarose gel electrophoresis of DNA harvested from SP2/0 cells treated with ART. The levels of nuclear factor kappa B p65 (NFkappaB p65) protein in nucleus and the inhibitor of NFkappaB (IkappaBalpha) in the cytoplasm were measured by western blot analysis and ELISA to evaluate NFkappaB p65 transcription activity indirectly. The results show that artesunate inhibited the proliferation and induced apoptosis of SP2/0 cells in a dose- and time-dependent manner. Artesunate also increased the proportion of SP2/0 cells in G0/G1 phase, while decreased the proportion of cells in G2/M or S phase. Additionally, artesunate treatment decreased the level of NFkappaB p65 protein in the nucleus, while increased the level of IkappaBalpha protein in the cytoplasm. The present result is the first report to show that artesunate may be useful in the treatment of MM.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
1865-3774
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
513-21
pubmed:meshHeading
pubmed-meshheading:19728025-Animals, pubmed-meshheading:19728025-Antineoplastic Agents, pubmed-meshheading:19728025-Apoptosis, pubmed-meshheading:19728025-Artemisinins, pubmed-meshheading:19728025-Cell Cycle, pubmed-meshheading:19728025-Cell Line, Tumor, pubmed-meshheading:19728025-Cell Proliferation, pubmed-meshheading:19728025-Cell Shape, pubmed-meshheading:19728025-Dose-Response Relationship, Drug, pubmed-meshheading:19728025-Drug Screening Assays, Antitumor, pubmed-meshheading:19728025-Mice, pubmed-meshheading:19728025-Mice, Inbred BALB C, pubmed-meshheading:19728025-Multiple Myeloma, pubmed-meshheading:19728025-Neoplasm Transplantation, pubmed-meshheading:19728025-Proteins, pubmed-meshheading:19728025-Time Factors, pubmed-meshheading:19728025-Transcription Factor RelA, pubmed-meshheading:19728025-Tumor Burden
pubmed:year
2009
pubmed:articleTitle
Effect of artesunate on inhibiting proliferation and inducing apoptosis of SP2/0 myeloma cells through affecting NFkappaB p65.
pubmed:affiliation
Department of Hematology, The Second Hospital of Hebei Medical University, 215, Heping Xi Road, 050000 Shijiazhuang City, People's Republic of China.
pubmed:publicationType
Journal Article